Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 21, 2017; 23(3): 505-515
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.505
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.505
Table 1 Baseline clinical characteristics of the enrolled patients
Characteristics | Patients (n = 1868) |
Mean age (range), yr | 65 (28-93) |
Gender | |
Male | 1072 (57.4) |
Female | 796 (42.6) |
Location | |
Colon | 892 (47.8) |
Rectum | 957 (51.2) |
Unknown | 19 (1.0) |
Histology | |
Well differentiated | 484 (25.9) |
Moderate differentiated | 1066 (57.1) |
Poorly differentiated | 139 (7.4) |
Unknown | 179 (9.6) |
Tumor stage | |
I | 281 (15.0) |
II | 551 (29.5) |
III | 667 (35.7) |
IV | 369 (19.8) |
Chemotherapy | |
No | 294 (15.8) |
Yes | 1574 (84.2) |
Table 2 Clinicopathological findings according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
Variable | NLR < 3.0 | NLR ≥ 3.0 | P value | PLR < 160 | PLR ≥ 160 | P value |
(n = 1086) | (n = 782) | (n = 973) | (n = 894) | |||
T stage | < 0.001 | < 0.001 | ||||
T1 | 112 | 39 | 112 | 39 | ||
T2 | 171 | 91 | 159 | 102 | ||
T3 | 668 | 498 | 579 | 587 | ||
T4 | 48 | 59 | 41 | 66 | ||
Unknown | 87 | 95 | 82 | 100 | ||
N stage | 0.854 | 0.443 | ||||
N0 | 589 | 434 | 543 | 480 | ||
N1 | 289 | 201 | 257 | 232 | ||
N2 | 196 | 138 | 164 | 170 | ||
Unknown | 12 | 9 | 9 | 12 | ||
Lymphatic invasion | 0.421 | 0.446 | ||||
Yes | 349 | 253 | 311 | 291 | ||
No | 587 | 391 | 524 | 453 | ||
Unknown | 150 | 138 | 138 | 150 | ||
Vascular invasion | 0.243 | 0.011 | ||||
Yes | 193 | 149 | 160 | 182 | ||
No | 742 | 496 | 675 | 562 | ||
Unknown | 151 | 137 | 138 | 150 | ||
Peri-neural invasion | 0.045 | |||||
Yes | 168 | 142 | 141 | 169 | 0.004 | |
No | 767 | 502 | 693 | 575 | ||
Unknown | 151 | 138 | 139 | 150 |
Table 3 Overall survival and disease free survival according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
NLR | PLR | |||
Low (< 3.0) | High (≥ 3.0) | Low (< 160) | High (≥ 160) | |
Overall survival | ||||
Stage I | ||||
3-yr OS rate | 97.0% | 98.2% | 99.3% | 94.7% |
5-yr OS rate | 92.6% | 91.9% | 94.8% | 87.3% |
Stage II | ||||
3-yr OS rate | 91.2% | 89.2% | 90.6% | 90.1% |
5-yr OS rate | 86.1% | 84.0% | 84.3% | 86.2% |
Stage III | ||||
3-yr OS rate | 79.6% | 73.4% | 82.1% | 71.4% |
5-yr OS rate | 69.3% | 60.9% | 69.6% | 61.9% |
Stage IV | ||||
3-yr OS rate | 39.8% | 21.2% | 33.9% | 27.4% |
5-yr OS rate | 34.3% | 18.1% | 28.6% | 23.8% |
Disease free survival | ||||
Stage I | ||||
3-yr DFS rate | 98.3% | 97.4% | 98.7% | 96.6% |
5-yr DFS rate | 96.1% | 95.6% | 97.2% | 93.3% |
Stage II | ||||
3-yr DFS rate | 88.5% | 89.3% | 87.8% | 89.9% |
5-yr DFS rate | 84.7% | 86.5% | 83.5% | 87.5% |
Stage III | ||||
3-yr DFS rate | 79.2% | 78.1% | 79.8% | 77.2% |
5-yr DFS rate | 75.2% | 68.6% | 74.5% | 70.5% |
Stage IV | ||||
3-yr DFS rate | 42.2% | 30.3% | 38.5% | 34.5% |
5-yr DFS rate | 37.5% | 26.8% | 34.3% | 30.4% |
Table 4 Prognostic factors by multivariate Cox regression analysis (Stage I and II)
Predictor | OS | DFS | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | ||||||
< 60 yr | 1.00 | 1.00 | ||||
≥ 60 yr | 1.72 | 1.08-2.76 | 0.023 | 1.44 | 0.91-2.28 | 0.123 |
Histology | ||||||
Well/moderate differentiated | 1.00 | 1.00 | ||||
Poorly differentiated | 1.57 | 0.72-3.47 | 0.260 | 2.46 | 1.25-4.81 | 0.009 |
T stage | ||||||
T1/T2 | 1.00 | 1.00 | ||||
T3/T4 | 1.66 | 0.95-2.90 | 0.074 | 1.62 | 0.94-2.80 | 0.084 |
Lymphatic invasion | ||||||
No | 1.00 | 1.00 | ||||
Yes | 0.77 | 0.46-1.28 | 0.306 | 1.02 | 0.62-1.68 | 0.931 |
Vascular invasion | ||||||
No | 1.00 | 1.00 | ||||
Yes | 2.36 | 1.46-3.84 | < 0.001 | 1.11 | 0.64-1.95 | 0.708 |
Peri-neural invasion | ||||||
No | 1.00 | 1.00 | ||||
Yes | 2.64 | 1.59-4.35 | < 0.001 | 3.08 | 1.86-5.09 | < 0.001 |
NLR | ||||||
Low NLR (< 3.0) | 1.00 | 1.00 | ||||
High NLR (≥ 3.0) | 1.16 | 0.76-1.76 | 0.498 | 1.06 | 0.69-1.62 | 0.788 |
PLR | ||||||
Low PLR (< 160) | 1.00 | 1.00 | ||||
High PLR (≥ 160) | 1.07 | 0.71-1.62 | 0.744 | 0.98 | 0.64-1.49 | 0.908 |
Table 5 Prognostic factors by multivariate Cox regression analysis (Stage III and IV)
Predictor | OS | DFS | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | ||||||
< 60 yr | 1.00 | 1.00 | ||||
≥ 60 yr | 1.46 | 1.13-1.89 | 0.004 | 1.10 | 0.84-1.44 | 0.479 |
Histology | ||||||
Well/Moderate differentiated | 1.00 | 1.00 | ||||
Poorly differentiated | 1.90 | 1.36-2.66 | < 0.001 | 1.46 | 0.98-2.14 | 0.058 |
T stage | ||||||
T1/T2 | 1.00 | 1.00 | ||||
T3/T4 | 2.61 | 1.51-4.51 | 0.001 | 3.13 | 1.69-5.78 | < 0.001 |
Lymphatic invasion | ||||||
No | 1.00 | 1.00 | ||||
Yes | 1.19 | 0.91-1.58 | 0.199 | 1.17 | 0.87-1.57 | 0.298 |
Vascular invasion | ||||||
No | 1.00 | 1.00 | ||||
Yes | 1.52 | 1.15-2.01 | 0.003 | 1.39 | 1.03-1.87 | 0.031 |
Peri-neural invasion | ||||||
No | 1.00 | 1.00 | ||||
Yes | 1.45 | 1.10-1.91 | 0.008 | 1.56 | 1.16-2.08 | 0.003 |
NLR | ||||||
Low NLR (< 3.0) | 1.00 | 1.00 | ||||
High NLR (≥ 3.0) | 1.44 | 1.14-1.83 | 0.003 | 1.43 | 1.11-1.85 | 0.005 |
PLR | ||||||
Low PLR (< 160) | 1.00 | 1.00 | ||||
High PLR (≥ 160) | 1.35 | 1.06-1.73 | 0.017 | 1.32 | 1.02-1.69 | 0.034 |
- Citation: Kim JH, Lee JY, Kim HK, Lee JW, Jung SG, Jung K, Kim SE, Moon W, Park MI, Park SJ. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer. World J Gastroenterol 2017; 23(3): 505-515
- URL: https://www.wjgnet.com/1007-9327/full/v23/i3/505.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i3.505